Stock analysis searches answered, part 1 of 43

Interprivate investment partners v, inc. units bullish and bearish analyst opinions

This section ties “Interprivate investment partners v, inc. units bullish and bearish analyst opinions” to InterPrivate Investment Partners V, Inc. (ticker IPVV, IPVVU, IPVVW), SEC Central Index Key 2105274, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-13. Nothing here is a recommendation to trade the security.

Financial trend for InterPrivate Investment Partners V, Inc. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$32,087 (2026-03-31) to $315,745 (2026-06-30), a change of +1084.0%; total assets was tagged only for 2026-06-30 at $202.86 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2105274, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures InterPrivate Investment Partners V, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on InterPrivate Investment Partners V, Inc. (CIK 2105274) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for InterPrivate Investment Partners V, Inc. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-06-04.

Current reports. Of the 3 8-K or 6-K reports in InterPrivate Investment Partners V, Inc.’s recent EDGAR index, the 3 listed here run from 2026-06-08 to 2026-07-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 32 recent EDGAR filings, InterPrivate Investment Partners V, Inc. most often filed 3 (7), CORRESP (6), SCHEDULE 13G (3), 8-K (3). A selection from 2026-06-10 to 2026-08-13:

The full record for CIK 2105274 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-01-27. Insider trades for InterPrivate Investment Partners V, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Itron abb eaton smart grid resilience latest news

Also searched as: itron abb eaton smart grid grid resilience latest news

A smart-grid resilience query naming Itron, ABB and Eaton; ABB is a Swiss company, so only Itron and Eaton are matched to EDGAR here. What follows is each company’s own disclosure trail as EDGAR showed it on Oct 25, 2026.

ITRON, INC. (ITRI; instruments for meas & testing of electricity & elec signals, incorporated in WA) — EDGAR lists the 8-K of 2026-07-28 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-05-08 covering 5.07 (submission of matters to a vote of security holders), 8.01 (other events). Year to 2025-12-31: annual sales of $2.37 billion, net result $301.06 million (10-K, 2026-02-17).

Eaton Corp plc (ETN; misc industrial & commercial machinery & equipment): its index shows the 8-K of 2026-10-16 covering 8.01 (other events), 9.01 (financial statements and exhibits); the 8-K of 2026-10-05 covering 5.02 (departure/election of directors or officers). Year to 2016-12-31: reported revenue $0 (10-K, 2017-02-22).

Item 2.02 — results of operations and financial condition — the item that accompanies an earnings release — appears this many times per company: ITRI 31 (latest 2026-07-28), ETN 40 (latest 2026-07-31).

ABB Ltd reports in Switzerland under SIX Swiss Exchange rules and publishes its results at global.abb, so its grid-automation news will not appear in EDGAR. Itron’s filings focus on metering and grid-edge networks, and Eaton reports its utility products within its Electrical segments, so resilience-related revenue is not broken out as a single line in either 10-K.

Pharming group n.v. bullish and bearish analyst opinions

This section ties “Pharming group n.v. bullish and bearish analyst opinions” to Pharming Group N.V. (ticker PHAR), SEC Central Index Key 1828316, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Netherlands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-02 by Pharming Group N.V. (CIK 1828316) — source document:

We were incorporated as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the laws of the Netherlands on November 11, 1988 under the name GENFARM B.V. On May 29, 1997, the Company was converted from a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) into a public company (naamloze vennootschap) named Pharming Holding N.V. Effective July 2, 1998, Pharming Holding N.V. was renamed Pharming Group N.V. We are registered with the Dutch Chamber of Commerce under number 28048592. Our ordinary shares are traded on Euronext Amsterdam under the symbol “PHARM.” As of December 22, 2020, our ADSs were admitted for listing on the Nasdaq under the symbol “PHAR” and began trading on Nasdaq Global Market.

Financial trend for Pharming Group N.V. from annual reports, periods 2018-12-31 to 2020-12-31: net income (loss) went from 24,993,000 EUR (2018-12-31) to 33,035,000 EUR (2020-12-31), a change of +32.2%; total assets went from 228,210,000 EUR (2019-12-31) to 340,758,000 EUR (2020-12-31), a change of +49.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1828316, tags Assets, ProfitLoss; 3 periods shown, dashes mark figures Pharming Group N.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Pharming Group N.V. (CIK 1828316) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-02. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 116 8-K or 6-K reports in Pharming Group N.V.’s recent EDGAR index, the 4 listed here run from 2026-09-25 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1828316 is on the EDGAR company page; the latest 20-F there is dated 2026-04-02 and the oldest filing in the recent index dates from 2020-10-14. Insider trades for Pharming Group N.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Btc googl lrcx msft vist stocks latest news and analysis

Bitcoin plus four tickers — Alphabet, Lam Research, Microsoft and Vista Energy; bitcoin itself is not a security issuer, so only the four companies are tabled. Filing records below were read from EDGAR on Oct 25, 2026, one registrant per row.

Alphabet Inc. (GOOGL; services-computer programming, data processing, etc., incorporated in DE) — recent current reports: the 8-K of 2026-08-10 covering 8.01 (other events), 9.01 (financial statements and exhibits); the 8-K of 2026-07-22 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2025-12-31: revenue of $402.84 billion, net income (loss) $132.17 billion (10-K, 2026-02-05).

LAM RESEARCH CORP (LRCX; special industry machinery, nec, incorporated in DE) filed the 8-K of 2026-10-21 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-08-27 covering 5.02 (departure/election of directors or officers). Year to 2011-06-26: FY revenue tagged at $3.24 billion, profit or loss $723.75 million (10-K, 2011-08-19).

MICROSOFT CORP (MSFT; services-prepackaged software, incorporated in WA) — EDGAR lists the 8-K of 2026-09-02 covering 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-07-29 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2010-06-30: annual sales of $62.48 billion, net result $18.76 billion (10-K, 2010-07-30).

Vista Energy, S.A.B. de C.V. (VIST; crude petroleum & natural gas, incorporated in Mexico): its index shows the 6-K of 2026-10-20; the 6-K of 2026-09-23. Year to 2024-12-31: reported revenue $1.65 billion, bottom line $477.52 million (20-F, 2025-04-09).

How often each filed an 8-K under Item 2.02, results of operations and financial condition — the item that accompanies an earnings release: GOOGL 13 (latest 2026-07-22), LRCX 46 (latest 2026-10-21), MSFT 24 (latest 2026-07-29), VIST 0.

Updated Oct 25, 2026 ET

Park-ohio holdings pkoh news october 2026

This section ties “Park-ohio holdings pkoh news october 2026” to PARK OHIO HOLDINGS CORP (ticker PKOH), SEC Central Index Key 76282, an EDGAR registrant classified as “Metal Forgings & Stampings” and organised in OH, formerly known as PARK OHIO INDUSTRIES INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-05 by PARK OHIO HOLDINGS CORP (CIK 76282) — source document:

Park-Ohio Holdings Corp. (“Holdings” or “ParkOhio”), incorporated in Ohio since 1998, is a diversified international company providing world-class customers with a supply chain management outsourcing service, capital equipment used on their production lines, and manufactured components used to assemble their products. References herein to “we” or “the Company” include, where applicable, Holdings and Park-Ohio Industries, Inc. and Holdings’ other direct and indirect subsidiaries. The Company operates through three reportable segments: Supply Technologies, Assembly Components and Engineered Products. As of December 31, 2025, we employed approximately 6,300 people. Total Supply Management ™ includes engineering and design support, part usage and cost analysis, supplier selection, quality assurance, bar coding, product packaging and tracking, just-in-time and point-of-use delivery, electronic billing services and ongoing technical support.

Financial trend for PARK OHIO HOLDINGS CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.49 billion (2022-12-31) to $1.60 billion (2025-12-31), a change of +7.1%; net income (loss) went from -$14.20 million (2022-12-31) to $23.80 million (2025-12-31), a change of +267.6%; total assets went from $1.44 billion (2022-12-31) to $1.42 billion (2025-12-31), a change of -1.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 76282, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures PARK OHIO HOLDINGS CORP did not tag for that period.

For the latest news, the fastest official source is the filing feed: PARK OHIO HOLDINGS CORP (CIK 76282) filed 108 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-05, and its overall latest filing is a 4 dated 2026-10-02. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 108 8-K or 6-K reports in PARK OHIO HOLDINGS CORP’s recent EDGAR index, the 4 listed here run from 2026-03-04 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 76282 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2011-11-10. Insider trades for PARK OHIO HOLDINGS CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gcm grosvenor private equity investment news october 2026

This section ties “Gcm grosvenor private equity investment news october 2026” to GCM Grosvenor Inc. (ticker GCMG), SEC Central Index Key 1819796, an EDGAR registrant classified as “Investment Advice” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-19 by GCM Grosvenor Inc. (CIK 1819796) — source document:

Over our 54-year history we have prided ourselves on our client-centric approach to alternative asset management. As a leading global solutions provider, we invest across all major alternative investment strategies and are highly flexible in how we structure our solutions, so that we can work to meet each client’s specific needs. As of December 31, 2025, we had $90.9 billion in AUM. Our central objectives are to provide our clients with choice, deliver innovative alternative investment offerings and generate competitive risk-adjusted returns. We partner with our institutional and individual clients to invest on their behalf across the private and public markets, either through portfolios customized to meet a client’s specific objectives or through specialized funds that are developed to meet broad market demands for strategies and risk-return objectives.

Financial trend for GCM Grosvenor Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $446.53 million (2022-12-31) to $557.57 million (2025-12-31), a change of +24.9%; net income (loss) went from $19.82 million (2022-12-31) to $45.37 million (2025-12-31), a change of +128.9%; total assets went from $488.93 million (2022-12-31) to $813.76 million (2025-12-31), a change of +66.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1819796, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures GCM Grosvenor Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: GCM Grosvenor Inc. (CIK 1819796) filed 45 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-10, and its overall latest filing is a 4 dated 2026-10-02. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 45 8-K or 6-K reports in GCM Grosvenor Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-10 to 2026-08-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1819796 is on the EDGAR company page; the latest 10-K there is dated 2026-02-19 and the oldest filing in the recent index dates from 2020-08-03. Insider trades for GCM Grosvenor Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Greenwich lifesciences press release glsi-100 october 2026

This section ties “Greenwich lifesciences press release glsi-100 october 2026” to Greenwich LifeSciences, Inc. (ticker GLSI), SEC Central Index Key 1799788, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-11, and this view starts from filings dated on or before 2026-01-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-06-01 by Greenwich LifeSciences, Inc. (CIK 1799788) (passage 2, continuing from the earlier excerpt) — source document:

Our Product Candidate GP2 is a HER2/ neu transmembrane peptide that elicits a targeted immune response against HER2/ neu -expressing cancers. Below is an image of a cell surface showing therapeutically relevant cell surface proteins in cancer. Breast cancers and other solid tumors with elevated expression of HER2/ neu protein are highly aggressive with an increased disease recurrence and a worse prognosis. GM-CSF Immunoadjuvant Recombinant human granulocyte macrophage colony-stimulating factor or GM-CSF (sargramostim, Leukine®) has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies. GP2 will be delivered in combination with GM-CSF to induce GP2 peptide specific immunity.

Financial trend for Greenwich LifeSciences, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from -$3.71 million (2025-09-30) to -$3.95 million (2026-06-30), a change of -6.4%; total assets went from $3.81 million (2025-09-30) to $8.88 million (2026-06-30), a change of +133.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1799788, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Greenwich LifeSciences, Inc. did not tag for that period.

Current reports. Of the 31 8-K or 6-K reports in Greenwich LifeSciences, Inc.’s recent EDGAR index, the 4 listed here run from 2023-04-13 to 2024-02-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1799788 is on the EDGAR company page; the latest 10-K there is dated 2026-06-01 and the oldest filing in the recent index dates from 2020-01-27. One example from this record is the 10-Q filed 2026-06-04 (document). Insider trades for Greenwich LifeSciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ge vernova vertiv bloom energy vistra data center power news october 21 2026

Also searched as: ge vernova vertiv bloom energy vistra data center power news october 21 2026 after:2026-10-20

Power-equipment, data-centre cooling, fuel-cell and power-generation companies bundled into one October 21, 2026 search about electricity for data centres. Filing records below were read from EDGAR on Oct 25, 2026, one registrant per row.

Bloom Energy Corp (BE; electrical industrial apparatus, incorporated in DE) — EDGAR lists the 8-K of 2026-10-22 covering 2.02 (results of operations and financial condition), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-07-28 covering 2.02 (results of operations and financial condition), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2025-12-31: annual sales of $2.02 billion (10-K, 2026-02-09).

GE Vernova Inc. (GEV; electronic & other electrical equipment (no computer equip), incorporated in DE): its index shows the 8-K of 2026-08-27 covering 5.02 (departure/election of directors or officers); the 8-K of 2026-07-22 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2025-12-31: reported revenue $38.07 billion, bottom line $4.88 billion (10-K, 2026-01-29).

Vertiv Holdings Co (VRT; electronic components, nec, incorporated in DE) filed the 8-K of 2026-09-24 covering 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-09-02 covering 1.01 (entry into a material definitive agreement), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2019-12-31: FY revenue tagged at $0, profit or loss -$140.80 million (10-K, 2020-03-12).

Vistra Corp. (VST; electric services, incorporated in DE) — EDGAR lists the 8-K of 2026-10-05 covering 1.01 (entry into a material definitive agreement), 2.03 (creation of a direct financial obligation), 9.01 (financial statements and exhibits); the 8-K of 2026-09-24 covering 1.01 (entry into a material definitive agreement), 8.01 (other events), 9.01 (financial statements and exhibits). Year to 2025-12-31: annual sales of $17.74 billion, net result $944.00 million (10-K, 2026-02-27).

How often each filed an 8-K under Item 2.02, results of operations and financial condition — the item that accompanies an earnings release: BE 33 (latest 2026-10-22), GEV 9 (latest 2026-07-22), VRT 28 (latest 2026-07-29), VST 37 (latest 2026-08-07).

Updated Oct 25, 2026 ET

Albemarle tesla plug power intel partnership joint venture latest

A lithium producer, an EV maker, a hydrogen fuel-cell company and a chipmaker searched together for a partnership or joint venture. Every name is matched to its own EDGAR record (checked Oct 25, 2026), since none of these companies reports on behalf of another.

PLUG POWER INC (PLUG; electrical industrial apparatus, incorporated in DE) — EDGAR lists the 8-K of 2026-10-15 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-09-23 covering 5.02 (departure/election of directors or officers). Year to 2025-12-31: annual sales of $709.92 million, net result -$1.63 billion (10-K, 2026-03-02).

ALBEMARLE CORP (ALB; plastic materials, synth resins & nonvulcan elastomers, incorporated in VA) filed the 8-K of 2026-09-03 covering 5.02 (departure/election of directors or officers), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-08-21 covering 5.02 (departure/election of directors or officers). Year to 2025-12-31: FY revenue tagged at $5.14 billion, profit or loss -$510.63 million (10-K, 2026-02-11).

Tesla, Inc. (TSLA; motor vehicles & passenger car bodies, incorporated in TX) filed the 8-K of 2026-10-21 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-10-02 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2025-12-31: FY revenue tagged at $94.83 billion, profit or loss $3.79 billion (10-K, 2026-01-29).

INTEL CORP (INTC; semiconductors & related devices, incorporated in DE) — EDGAR lists the 8-K of 2026-08-12 covering 7.01 (regulation fd disclosure), 8.01 (other events), 9.01 (financial statements and exhibits); the 8-K of 2026-07-23 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2025-12-27: annual sales of $52.85 billion, net result -$267.00 million (10-K, 2026-01-23).

Frequency of Item 1.01 (entry into a material definitive agreement — the item a significant partnership or contract would be filed under) in recent filings — PLUG 39 (latest 2026-07-13), ALB 18 (latest 2026-03-25), TSLA 19 (latest 2026-09-29), INTC 9 (latest 2025-08-29).

Updated Oct 25, 2026 ET

Allarity therapeutics

This section ties “Allarity therapeutics” to Allarity Therapeutics, Inc. (ticker ALLR), SEC Central Index Key 1860657, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-09. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by Allarity Therapeutics, Inc. (CIK 1860657) — source document:

We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell’s sensitivity to a specific cancer therapeutic. Once defined, the DRP® gene expression signature can then be assessed in cancer tissue biopsies from patients to identify those cancers that share this signature of drug sensitivity, and by extension, to identify those patients who may then be most likely to receive benefit from that specific anti-cancer therapeutic. We have developed and published DRP® signatures for dozens of anti-cancer therapeutics.

Financial trend for Allarity Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2024-12-31) to $320,000 (2025-12-31); net income (loss) went from -$16.06 million (2022-12-31) to -$11.23 million (2025-12-31), a change of +30.1%; total assets went from $14.54 million (2022-12-31) to $18.26 million (2025-12-31), a change of +25.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1860657, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures Allarity Therapeutics, Inc. did not tag for that period.

Allarity Therapeutics, Inc. has 400 filings in its recent EDGAR index, including 5 annual reports and 15 quarterly reports; its newest filing is a 4 from 2026-10-09.

Current reports. Of the 153 8-K or 6-K reports in Allarity Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-14 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1860657 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2021-05-27. Insider trades for Allarity Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alta equipment group altg news october 2026

This section ties “Alta equipment group altg news october 2026” to ALTA EQUIPMENT GROUP INC. (ticker ALTG, ALTG-PA), SEC Central Index Key 1759824, an EDGAR registrant classified as “Wholesale-Industrial Machinery & Equipment” and organised in DE, formerly known as B. Riley Principal Merger Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-02. Nothing here is a recommendation to trade the security.

Financial trend for ALTA EQUIPMENT GROUP INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.57 billion (2022-12-31) to $1.84 billion (2025-12-31), a change of +16.8%; net income (loss) went from $9.30 million (2022-12-31) to -$80.30 million (2025-12-31), a change of -963.4%; total assets went from $1.29 billion (2022-12-31) to $1.34 billion (2025-12-31), a change of +3.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1759824, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures ALTA EQUIPMENT GROUP INC. did not tag for that period.

For the latest news, the fastest official source is the filing feed: ALTA EQUIPMENT GROUP INC. (CIK 1759824) filed 126 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-02, and its overall latest filing is a 8-K dated 2026-10-02. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 126 8-K or 6-K reports in ALTA EQUIPMENT GROUP INC.’s recent EDGAR index, the 4 listed here run from 2026-05-29 to 2026-10-02, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 519 recent EDGAR filings, ALTA EQUIPMENT GROUP INC. most often filed 4 (159), 8-K (126), 3 (25), SC 13D/A (24). A selection from 2026-06-09 to 2026-08-14:

The full record for CIK 1759824 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2018-12-10. Insider trades for ALTA EQUIPMENT GROUP INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Blue water acquisition corp iii forecast and analysis

This section ties “Blue water acquisition corp iii forecast and analysis” to Blue Water Acquisition Corp. III (ticker BLUW, BLUWU, BLUWW), SEC Central Index Key 2050501, an EDGAR registrant classified as “Blank Checks” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-14 by Blue Water Acquisition Corp. III (CIK 2050501) — source document:

References in this Annual Report on Form 10-K (the “Annual Report” or the “Form 10-K”) to “we,” “us,” “our”, “Blue Water” or the “Company” refer to Blue Water Acquisition Corp. III. Overview We are a blank check company incorporated on November 1, 2024, as a Cayman Islands exempted company with no material operations of our own. We were formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (the “Business Combination”). We may pursue an initial Business Combination in any business or industry but expect to focus on biotechnology, healthcare and technology companies. Our units include shares of a Cayman Islands blank check company instead of the shares of the operating entities with whom we may combine.

Financial trend for Blue Water Acquisition Corp. III from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $4.67 million; total assets went from $25,000 (2024-12-31) to $258.91 million (2025-12-31), a change of +1035543.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2050501, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Blue Water Acquisition Corp. III did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Blue Water Acquisition Corp. III (CIK 2050501) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-04-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Blue Water Acquisition Corp. III — registration statements, prospectuses and merger proxies — are filed on EDGAR; 6 such filings (424B4, S-1, S-1/A, S-1MEF) appear in its recent index, the newest dated 2025-06-11.

Current reports. Of the 8 8-K or 6-K reports in Blue Water Acquisition Corp. III’s recent EDGAR index, the 4 listed here run from 2025-12-31 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2050501 is on the EDGAR company page; the latest 10-K there is dated 2026-04-14 and the oldest filing in the recent index dates from 2025-02-20. Insider trades for Blue Water Acquisition Corp. III appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Burtech acquisition corp ii forecast and analysis

This section ties “Burtech acquisition corp ii forecast and analysis” to Burtech Acquisition Corp II (ticker BRKH, BRKHU, BRKHW), SEC Central Index Key 2098707, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14. Nothing here is a recommendation to trade the security.

Financial trend for Burtech Acquisition Corp II from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$15,088 (2026-03-31) to $168,096 (2026-06-30), a change of +1214.1%; total assets went from $119,841 (2026-03-31) to $81.53 million (2026-06-30), a change of +67930.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2098707, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Burtech Acquisition Corp II did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Burtech Acquisition Corp II (CIK 2098707) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Burtech Acquisition Corp II — registration statements, prospectuses and merger proxies — are filed on EDGAR; 2 such filings (424B4, S-1) appear in its recent index, the newest dated 2026-05-26.

Current reports. Of the 3 8-K or 6-K reports in Burtech Acquisition Corp II’s recent EDGAR index, the 3 listed here run from 2026-05-26 to 2026-07-10, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 30 recent EDGAR filings, Burtech Acquisition Corp II most often filed 4 (6), 3 (6), 8-K (3), 10-Q (2). A selection from 2026-06-09 to 2026-08-14:

The full record for CIK 2098707 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-12-17. Insider trades for Burtech Acquisition Corp II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pelagos insurance capital plgo latest news

This section ties “Pelagos insurance capital plgo latest news” to Pelagos Insurance Capital Ltd (ticker PLGO), SEC Central Index Key 1636639, an EDGAR registrant classified as “Fire, Marine & Casualty Insurance” and organised in Bermuda, formerly known as Fidelis Insurance Holdings Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-05 by Pelagos Insurance Capital Ltd (CIK 1636639) — source document:

Company Information Fidelis Insurance Group is a global specialty insurer headquartered in Bermuda, with offices in Ireland and the United Kingdom. The Group is comprised of a holding company, Fidelis Insurance Holdings Limited (“FIHL”), a Bermuda exempted company, incorporated under the Bermuda Companies Act on August 22, 2014, and its three principal operating subsidiaries: Fidelis Insurance Bermuda Limited (“FIBL”), Fidelis Underwriting Limited (“FUL”) and Fidelis Insurance Ireland DAC (“FIID”). The Group also has its own service company, FIHL (UK) Services Limited, with a branch in Ireland, and a Lloyd’s corporate member, Nameco (No 1404) Limited (the “Fidelis IG Corporate Member”), established on May 22, 2024 as a wholly owned subsidiary of FIBL, to facilitate its participation in Lloyd’s Syndicate 3123’s underwriting activity.

Financial trend for Pelagos Insurance Capital Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.51 billion (2022-12-31) to $2.50 billion (2025-12-31), a change of +65.7%; net income (loss) went from $52.60 million (2022-12-31) to $113.30 million (2024-12-31), a change of +115.4%; total assets went from $8.31 billion (2022-12-31) to $12.44 billion (2025-12-31), a change of +49.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1636639, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Pelagos Insurance Capital Ltd did not tag for that period.

For the latest news, the fastest official source is the filing feed: Pelagos Insurance Capital Ltd (CIK 1636639) filed 53 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-14, and its overall latest filing is a 4 dated 2026-10-14. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 53 8-K or 6-K reports in Pelagos Insurance Capital Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-03 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1636639 is on the EDGAR company page; the latest 20-F there is dated 2026-03-05 and the oldest filing in the recent index dates from 2015-03-19. Insider trades for Pelagos Insurance Capital Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Satellos

This section ties “Satellos” to Satellos Bioscience Inc. (ticker MSLE), SEC Central Index Key 1421642, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Canada (Federal Level), formerly known as ICO THERAPEUTICS INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-21. Nothing here is a recommendation to trade the security.

Financial trend for Satellos Bioscience Inc. from annual reports, periods 2023-12-31 to 2024-12-31: net income (loss) was tagged only for 2024-12-31 at -28,099,000 CAD; total assets went from 44,298,000 CAD (2023-12-31) to 73,017,000 CAD (2024-12-31), a change of +64.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1421642, tags Assets, ProfitLoss; 2 periods shown, dashes mark figures Satellos Bioscience Inc. did not tag for that period.

Satellos Bioscience Inc. has 52 filings in its recent EDGAR index, including 1 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-10-21.

Current reports. Of the 28 8-K or 6-K reports in Satellos Bioscience Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 52 recent EDGAR filings, Satellos Bioscience Inc. most often filed 6-K (28), D (8), SUPPL (2), F-X (2). A selection from 2026-05-12 to 2026-08-14:

The full record for CIK 1421642 is on the EDGAR company page; the latest 40-F there is dated 2026-03-27 and the oldest filing in the recent index dates from 2007-12-17. Insider trades for Satellos Bioscience Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Muzero acquisition corp class a ordinary shares bullish and bearish analyst opinions

This section ties “Muzero acquisition corp class a ordinary shares bullish and bearish analyst opinions” to Muzero Acquisition Corp (ticker MUZE, MUZEU, MUZEW), SEC Central Index Key 2093484, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by Muzero Acquisition Corp (CIK 2093484) — source document:

We are a blank check company incorporated on October 10, 2025 as a Cayman Islands exempted company and formed for the purpose of effecting a Business Combination with one or more businesses or entities. We may pursue an initial Business Combination in any business or industry. To date, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering and (iii) searching for and consummating a Business Combination. As of the date of this Report, we have not selected any specific Business Combination target. We have generated no operating revenues to date, and we do not expect that we will generate operating revenues until we consummate our initial Business Combination.

Financial trend for Muzero Acquisition Corp from quarterly and annual reports (three-month periods), periods 2025-12-31 to 2026-06-30: net income (loss) went from -$49,541 (2025-12-31) to $1.66 million (2026-06-30), a change of +3457.1%; total assets went from $198,950 (2025-12-31) to $205.23 million (2026-06-30), a change of +103055.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2093484, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Muzero Acquisition Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Muzero Acquisition Corp (CIK 2093484) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Muzero Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-02-02.

Current reports. Of the 3 8-K or 6-K reports in Muzero Acquisition Corp’s recent EDGAR index, the 3 listed here run from 2026-02-03 to 2026-03-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2093484 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2025-12-03. Insider trades for Muzero Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Celularity

This section ties “Celularity” to Celularity Inc (ticker CELU), SEC Central Index Key 1752828, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as GX Acquisition Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-30 by Celularity Inc (CIK 1752828) — source document:

The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life. Aging is known to be a major risk factor for many degenerative disorders and diseases across multiple high-value therapeutic areas, including immunology and regenerative medicine. Common to all degenerative disorders and diseases is the progressive loss of function or structure (or both) of affected tissues and organs driven by underlying cellular dysfunction. These processes directly impact regenerative capacity, healthspan and overall lifespan. Likewise, age-associated immunosenescence and other physiological changes contribute to increased vulnerability to infections. Infections further exacerbate aging-related decline and are increasingly associated with frailty and adverse clinical outcomes.

Financial trend for Celularity Inc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $17.98 million (2022-12-31) to $26.55 million (2025-12-31), a change of +47.7%; net income (loss) went from $14.19 million (2022-12-31) to -$91.72 million (2025-12-31), a change of -746.3%; total assets went from $401.07 million (2022-12-31) to $107.33 million (2025-12-31), a change of -73.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1752828, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Celularity Inc did not tag for that period.

Celularity Inc has 558 filings in its recent EDGAR index, including 7 annual reports and 22 quarterly reports; its newest filing is a 10-Q from 2026-10-20.

Current reports. Of the 119 8-K or 6-K reports in Celularity Inc’s recent EDGAR index, the 4 listed here run from 2026-08-07 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1752828 is on the EDGAR company page; the latest 10-K/A there is dated 2026-10-20 and the oldest filing in the recent index dates from 2018-11-05. Insider trades for Celularity Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Commonwealth fusion systems arc virginia plant progress latest

Also searched as: commonwealth fusion systems arc virginia plant latest progress

This section ties “Commonwealth fusion systems arc virginia plant progress latest” to Commonwealth Fusion Systems LLC (ticker none listed), SEC Central Index Key 1744079, an EDGAR registrant classified as “no SIC description” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a D dated 2021-12-02. Nothing here is a recommendation to trade the security.

For the latest news, the fastest official source is the filing feed: Commonwealth Fusion Systems LLC (CIK 1744079) filed 0 current reports (8-K or 6-K) in its recent EDGAR window, and its overall latest filing is a D dated 2021-12-02. Companies must file an 8-K within four business days of most material events.

What kind of filer this is matters for “Commonwealth fusion systems arc virginia plant progress latest”: Commonwealth Fusion Systems LLC’s EDGAR record from 2018-06-27 to 2021-12-02 consists only of D/A filings; Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it.

Other filings. Across its 4 recent EDGAR filings, Commonwealth Fusion Systems LLC most often filed D (3), D/A (1). A selection from 2018-06-27 to 2021-12-02:

The full record for CIK 1744079 is on the EDGAR company page and the oldest filing in the recent index dates from 2018-06-27. Insider trades for Commonwealth Fusion Systems LLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Robinhood of user of growth of and of terawulf of ai of data-center of power of deals of news

Also searched as: robinhood the user the growth the and the terawulf the ai the data-center the power the deals the news; robinhood user growth and terawulf ai data-center power deals news; robinhood with user with growth with and with terawulf with ai with data-center with power with deals with news; robinhood a user a growth a and a terawulf a ai a data-center a power a deals a news

A garbled query with “of” between each word, pairing Robinhood with TeraWulf on AI, data-centre and power deals. Every name is matched to its own EDGAR record (checked Oct 25, 2026), since none of these companies reports on behalf of another.

Robinhood Markets, Inc. (HOOD; security brokers, dealers & flotation companies, incorporated in DE) — EDGAR lists the 8-K of 2026-07-29 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-06-26 covering 5.02 (departure/election of directors or officers). Year to 2025-12-31: annual sales of $4.47 billion, net result $1.88 billion (10-K/A, 2026-02-20).

TERAWULF INC. (WULF; finance services, incorporated in DE): its index shows the 8-K of 2026-08-05 covering 2.02 (results of operations and financial condition), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-07-06 covering 8.01 (other events), 9.01 (financial statements and exhibits). Year to 2024-12-31: reported revenue $140.05 million, bottom line -$72.42 million (10-K, 2026-02-27).

Frequency of Item 2.01 (completion of an acquisition or disposition of assets) in recent filings — HOOD 0, WULF 0.

Stripped of the filler words, the query is about two unrelated stories: Robinhood’s funded-customer growth, reported monthly in its operating-data releases, and TeraWulf’s move from bitcoin mining toward hosting AI and high-performance computing workloads at its power sites. No joint deal between the two companies appears in either company’s filing index.

Albemarle tesla plug power intel new partnership joint venture

Sample EDGAR registrant names, term by term — containing “albemarle”: ALBEMARLE HEDGE INVESTORS LP (CIK 1412003), ALBEMARLE HOLDINGS CORP (CIK 1620352), ALBEMARLE HOLDINGS II CORP (CIK 1620354); containing “tesla”: TESLA GROUP HOLDINGS PTY LTD (CIK 1345028), TESLA JP/PI LLC (CIK 1402995), TESLA LIFE SCIENCES, LLC (CIK 1588360); containing “plug”: PLUG & PLAY FUTURE COMMERCE FUND I, L.P. (CIK 1794663), PLUG & PLAY NEW JERSEY FUND I, L.P. (CIK 2031776), PLUG & PLAY NEW JERSEY FUND I-A, L.P. (CIK 2154167); containing “power”: 968 CHARTER ACT, A SERIES OF POWER SERIES LLC (CIK 1795967), A PROMISE TO WIN, A SERIES OF POWER SERIES LLC (CIK 1841481), A-POWER ENERGY GENERATION SYSTEMS, LTD. (CIK 1399233); containing “intel”: ARCHIVE INTEL, INC. (CIK 2022895), ARIAS INTEL CORP. (CIK 1585755), BFE INTEL SPV, LP (CIK 2101836). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “albemarle” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

For the “new partnership” angle, the useful test is timing: a newly signed agreement shows up first as an 8-K filed within four business days of signing, then in the next 10-Q. Albemarle files under CIK 915913, Tesla under CIK 1318605, Plug Power under CIK 1093691 and Intel under CIK 50863. If none of their recent 8-Ks mention a counterparty from this list, there is no disclosed new partnership among them, whatever social-media posts suggest.

Updated Oct 25, 2026 ET

Aura renewable acquisitions plc bullish and bearish analyst opinions

The legal-form ending in “Aura renewable acquisitions plc” is the clue: “plc” is the UK public limited company form, so the company’s accounts are filed at Companies House. A company of that kind reports in the United Kingdom, so the place to read its annual report and announcements is Companies House and the London Stock Exchange RNS announcements — find-and-update.company-information.service.gov.uk.

No SEC filer could be matched to “Aura renewable acquisitions plc bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Aura renewable acquisitions plc”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “aura” (search terms considered: aura, renewable, acquisitions).

Even the shorter phrase “Aura renewable acquisitions” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (aura, renewable, acquisitions) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in the United Kingdom. Companies there file with the London Stock Exchange and the FCA National Storage Mechanism rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “aura” is therefore the the United Kingdom regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 41 entities whose registered name contains the word “aura”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “aura” 41, “renewable” 287, “acquisitions” 495. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “aura” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report; a SPAC, IPO or merger involving “aura” would leave an S-1, F-1, S-4 or 425 filing on EDGAR once it is public, and its absence means no U.S. registered offering has been filed under that name. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Icg advisors private equity allocation

This section ties “Icg advisors private equity allocation” to ICG Advisors, LLC (ticker none listed), SEC Central Index Key 2089727, an EDGAR registrant classified as “no SIC description” and organised in CA. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 13F-HR/A dated 2026-10-20. Nothing here is a recommendation to trade the security.

ICG Advisors, LLC has 7 filings in its recent EDGAR index; its newest filing is a 13F-HR/A from 2026-10-20.

What kind of filer this is matters for “Icg advisors private equity allocation”: ICG Advisors, LLC’s EDGAR record from 2026-01-28 to 2026-10-20 consists only of 13F holdings reports as an institutional investment manager; 13F-HR/A filings; N-PX filings. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it.

Other filings. Across its 7 recent EDGAR filings, ICG Advisors, LLC most often filed 13F-HR (4), 13F-HR/A (2), N-PX (1). A selection from 2026-04-23 to 2026-10-20:

The full record for CIK 2089727 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-01-28. Insider trades for ICG Advisors, LLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Amg critical materials n.v. bullish and bearish analyst opinions

“N.V.” and “B.V.” are Dutch public and private limited company forms. The name “Amg critical materials n.v.” therefore points to a company organised in the Netherlands, and its official disclosures are on the Dutch AFM registers and the KvK commercial register (www.afm.nl), not on EDGAR.

No SEC filer could be matched to “Amg critical materials n.v. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Amg critical materials n.v.” appears in 471+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “amg” (search terms considered: amg, critical, materials).

A broader EDGAR full-text search for the shorter phrase “Amg critical materials” finds 4914+ filing documents; among the top 100, the filers mentioning it most are Global X Funds (CIK 0001432353) (19); VanEck ETF Trust (CIK 0001137360) (14); iShares, Inc. (CIK 0000930667) (14). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Amg critical materials n.v.”, filings range from 2023-07-27 to 2026-10-23. The filers whose documents mention it most often are Global X Funds (CIK 0001432353) (20 hits); iShares, Inc. (CIK 0000930667) (13 hits); Perpetual Americas Funds Trust (CIK 0001830437) (10 hits); Invesco Exchange-Traded Fund Trust II (CIK 0001378872) (7 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 60 entities whose registered name contains the word “amg”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “amg” 60, “critical” 110, “materials” 343. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “amg” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Berto acquisition corp. ii forecast and analysis

This section ties “Berto acquisition corp. ii forecast and analysis” to Berto Acquisition Corp. II (ticker GUAC, GUACU, GUACW), SEC Central Index Key 2081515, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14. Nothing here is a recommendation to trade the security.

Analyst ratings, price targets and “bullish” or “bearish” calls on Berto Acquisition Corp. II (CIK 2081515) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Berto Acquisition Corp. II — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, S-1, S-1/A, S-1MEF) appear in its recent index, the newest dated 2026-05-18.

Current reports. Of the 4 8-K or 6-K reports in Berto Acquisition Corp. II’s recent EDGAR index, the 4 listed here run from 2026-05-18 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 27 recent EDGAR filings, Berto Acquisition Corp. II most often filed 3 (6), 8-K (4), SCHEDULE 13G (3), 4 (2). A selection from 2026-05-18 to 2026-08-14:

The full record for CIK 2081515 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-20. Insider trades for Berto Acquisition Corp. II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

(fluence energy, inc. or flnc or shoals technologies group, inc. or shls or array technologies, inc. or arry or nextpower inc. or nxt) and (latest news or contracts or earnings or guidance)

A Boolean search across four solar and storage hardware suppliers — Fluence, Shoals, Array and Nextpower — written with tickers as alternatives. Filing records below were read from EDGAR on Oct 25, 2026, one registrant per row.

Array Technologies, Inc. (ARRY; semiconductors & related devices, incorporated in DE) filed the 8-K of 2026-08-31 covering 7.01 (regulation fd disclosure), 8.01 (other events), 9.01 (financial statements and exhibits); the 8-K of 2026-08-20 covering 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2025-12-31: FY revenue tagged at $1.28 billion, profit or loss -$52.23 million (10-K, 2026-02-25).

Nextpower Inc. (NXT; semiconductors & related devices, incorporated in DE) — EDGAR lists the 8-K of 2026-08-19 covering 5.03 (amendments to articles of incorporation or bylaws), 5.07 (submission of matters to a vote of security holders), 9.01 (financial statements and exhibits); the 8-K of 2026-07-30 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2026-03-31: annual sales of $3.56 billion, net result $585.88 million (10-K, 2026-05-19).

Fluence Energy, Inc. (FLNC; miscellaneous electrical machinery, equipment & supplies) filed the 8-K of 2026-10-09 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits); the 8-K of 2026-09-16 covering 5.02 (departure/election of directors or officers), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2025-09-30: FY revenue tagged at $2.26 billion, profit or loss -$48.31 million (10-K, 2025-11-25).

Shoals Technologies Group, Inc. (SHLS; semiconductors & related devices, incorporated in DE) — EDGAR lists the 8-K of 2026-08-31 covering 1.01 (entry into a material definitive agreement), 2.03 (creation of a direct financial obligation), 9.01 (financial statements and exhibits); the 8-K of 2026-08-04 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2025-12-31: annual sales of $475.33 million, net result $33.57 million (10-K, 2026-02-24).

How often each filed an 8-K under Item 1.01, entry into a material definitive agreement — the item a significant partnership or contract would be filed under: ARRY 12 (latest 2026-07-16), NXT 4 (latest 2025-09-08), FLNC 6 (latest 2026-04-03), SHLS 7 (latest 2026-08-31).

Updated Oct 25, 2026 ET

Fiserv fis launches merchant acquiring payment software bundle

A query about a merchant-acquiring and payments-software bundle naming the two U.S. payment processors Fiserv and FIS, which are separate companies despite similar names. Every name is matched to its own EDGAR record (checked Oct 25, 2026), since none of these companies reports on behalf of another.

FISERV INC (FISV; services-business services, nec, incorporated in WI): its index shows the 8-K of 2026-10-23 covering 5.02 (departure/election of directors or officers); the 8-K of 2026-09-22 covering 5.02 (departure/election of directors or officers). Year to 2025-12-31: reported revenue $21.19 billion, bottom line $3.48 billion (10-K, 2026-02-19).

Fidelity National Information Services, Inc. (FIS; services-business services, nec) filed the 8-K of 2026-08-04 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-06-18 covering 5.02 (departure/election of directors or officers). Year to 2025-12-31: FY revenue tagged at $10.68 billion, profit or loss $382.00 million (10-K, 2026-02-24).

Frequency of Item 2.01 (completion of an acquisition or disposition of assets) in recent filings — FISV 1 (latest 2019-07-29), FIS 3 (latest 2026-01-12).

Product launches are rarely filed as 8-Ks unless they are material, so a merchant-acquiring bundle would normally be announced by press release on each company’s investor site. Fiserv’s merchant business includes the Clover point-of-sale platform, while FIS separated most of its own merchant unit, Worldpay, in a 2024 transaction, which matters when comparing the two companies’ acquiring offerings.

Miluna acquisition corp class a ordinary share bullish and bearish analyst opinions

This section ties “Miluna acquisition corp class a ordinary share bullish and bearish analyst opinions” to Miluna Acquisition Corp (ticker MMTX, MMTXU, MMTXW), SEC Central Index Key 2077033, an EDGAR registrant classified as “Services-Computer Programming Services” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a S-4/A dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-12 by Miluna Acquisition Corp (CIK 2077033) — source document:

We are a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses, which we refer to throughout this Annual Report as our initial business combination. We have not selected any business combination target. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, except that we will not pursue a prospective target company based in or having the majority of its operations in the PRC. Throughout this Annual Report, “PRC” refers to the People’s Republic of China, including the Hong Kong Special Administrative Region and the Macau Special Administrative Region and, for the purpose of this Annual Report only, excluding Taiwan.

Financial trend for Miluna Acquisition Corp from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from -$19,000 (2025-09-30) to $93,409 (2026-06-30), a change of +591.6%; total assets went from $244,722 (2025-09-30) to $70.91 million (2026-06-30), a change of +28876.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2077033, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Miluna Acquisition Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Miluna Acquisition Corp (CIK 2077033) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-02-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Miluna Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 9 such filings (424B4, 425, S-1, S-1/A, S-1MEF) appear in its recent index, the newest dated 2026-10-16.

Current reports. Of the 8 8-K or 6-K reports in Miluna Acquisition Corp’s recent EDGAR index, the 4 listed here run from 2025-12-12 to 2026-04-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2077033 is on the EDGAR company page; the latest 10-K there is dated 2026-02-12 and the oldest filing in the recent index dates from 2025-07-25. Insider trades for Miluna Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Virtra

This section ties “Virtra” to VirTra, Inc (ticker VTSI), SEC Central Index Key 1085243, an EDGAR registrant classified as “Miscellaneous Manufacturing Industries” and organised in NV, formerly known as VIRTRA SYSTEMS INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-15. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-26 by VirTra, Inc (CIK 1085243) — source document:

We are a corporation organized and existing under the laws of the State of Nevada. The original business started in 1993 as Ferris Productions, Inc. In September 2001, Ferris Productions, Inc. merged with GameCom, Inc. to ultimately become VirTra Systems, Inc., a Texas corporation. Effective as of October 1, 2016, we completed a conversion from a Texas corporation to a Nevada corporation pursuant to a Redomestication Plan of Conversion (the “Plan of Conversion”) that was approved by our Board of Directors on June 23, 2016, and by our stockholders on September 16, 2016. As part of the Plan of Conversion, we filed Articles of Incorporation in Nevada whereby we changed our name from VirTra Systems, Inc. to VirTra, Inc. and revised our capitalization.

Financial trend for VirTra, Inc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $747,977 (2023-12-31) to $185,971 (2025-12-31), a change of -75.1%; net income (loss) went from $1.96 million (2022-12-31) to $258,446 (2025-12-31), a change of -86.8%; total assets went from $53.81 million (2022-12-31) to $65.14 million (2025-12-31), a change of +21.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1085243, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures VirTra, Inc did not tag for that period.

VirTra, Inc has 441 filings in its recent EDGAR index, including 9 annual reports and 27 quarterly reports; its newest filing is a 4 from 2026-09-15.

Current reports. Of the 115 8-K or 6-K reports in VirTra, Inc’s recent EDGAR index, the 4 listed here run from 2026-03-26 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1085243 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 1999-12-06. Insider trades for VirTra, Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Biote medical mobile apps

This section ties “Biote medical mobile apps” to biote Corp. (ticker BTMD), SEC Central Index Key 1819253, an EDGAR registrant classified as “Medicinal Chemicals & Botanical Products” and organised in an unstated jurisdiction, formerly known as Haymaker Acquisition Corp. III. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-09-18. Nothing here is a recommendation to trade the security.

Financial trend for biote Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $164.96 million (2022-12-31) to $192.22 million (2025-12-31), a change of +16.5%; net income (loss) went from -$969,000 (2022-12-31) to $27.05 million (2025-12-31), a change of +2891.0%; total assets went from $111.64 million (2022-12-31) to $107.61 million (2025-12-31), a change of -3.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1819253, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures biote Corp. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for biote Corp. (CIK 1819253) lists its business address as 1875 W. WALNUT HILL LN #100, IRVING, TX, which helps confirm you are on the right company’s site.

Current reports. Of the 63 8-K or 6-K reports in biote Corp.’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 410 recent EDGAR filings, biote Corp. most often filed 4 (105), 8-K (63), 424B3 (49), 3 (23). A selection from 2026-08-07 to 2026-09-18:

The full record for CIK 1819253 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2020-08-06. Insider trades for biote Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Radware ip device cve

Also searched as: cve radware ip device

This section ties “Radware ip device cve” to RADWARE LTD (ticker RDWR), SEC Central Index Key 1094366, an EDGAR registrant classified as “Services-Business Services, NEC” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-07. Nothing here is a recommendation to trade the security.

Vulnerability records for Radware. Security flaws are catalogued by the U.S. National Vulnerability Database (NVD), run by NIST, not by the SEC. A keyword query of the NVD on Oct 25, 2026 returned 9 CVE entries whose descriptions mention Radware; 2 of them were published in 2026, the newest being CVE-2026-12812 on 2026-06-21. Severity scores below are the CVSS base scores NVD lists; vendor advisories give fixed versions.

Financial trend for RADWARE LTD from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $293.43 million (2022-12-31) to $301.85 million (2025-12-31), a change of +2.9%; net income (loss) went from -$166,000 (2022-12-31) to $20.26 million (2025-12-31), a change of +12303.0%; total assets went from $643.59 million (2022-12-31) to $671.16 million (2025-12-31), a change of +4.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1094366, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures RADWARE LTD did not tag for that period.

Current reports. Of the 283 8-K or 6-K reports in RADWARE LTD’s recent EDGAR index, the 4 listed here run from 2026-05-27 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1094366 is on the EDGAR company page; the latest 20-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 2000-02-14. Insider trades for RADWARE LTD appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Check point gaia os cve

Also searched as: cve check point gaia os

This section ties “Check point gaia os cve” to CHECK POINT SOFTWARE TECHNOLOGIES LTD (ticker CHKP), SEC Central Index Key 1015922, an EDGAR registrant classified as “Services-Prepackaged Software” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 144 dated 2026-10-22. Nothing here is a recommendation to trade the security.

Vulnerability records for Check Point Gaia. Security flaws are catalogued by the U.S. National Vulnerability Database (NVD), run by NIST, not by the SEC. A keyword query of the NVD on Oct 25, 2026 returned 3 CVE entries whose descriptions mention Check Point Gaia; 1 of them were published in 2026, the newest being CVE-2026-62145 on 2026-07-22. Severity scores below are the CVSS base scores NVD lists; vendor advisories give fixed versions.

Financial trend for CHECK POINT SOFTWARE TECHNOLOGIES LTD from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.33 billion (2022-12-31) to $2.73 billion (2025-12-31), a change of +17.0%; net income (loss) went from $796.90 million (2022-12-31) to $1.06 billion (2025-12-31), a change of +32.6%; total assets went from $5.72 billion (2022-12-31) to $7.81 billion (2025-12-31), a change of +36.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1015922, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures CHECK POINT SOFTWARE TECHNOLOGIES LTD did not tag for that period.

Current reports. Of the 221 8-K or 6-K reports in CHECK POINT SOFTWARE TECHNOLOGIES LTD’s recent EDGAR index, the 4 listed here run from 2026-07-22 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1015922 is on the EDGAR company page; the latest 20-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 1997-02-14. Insider trades for CHECK POINT SOFTWARE TECHNOLOGIES LTD appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cisco unity connection cve

Also searched as: unity connection cve cisco; cve cisco unity connection

This section ties “Cisco unity connection cve” to CISCO SYSTEMS, INC. (ticker CSCO), SEC Central Index Key 858877, an EDGAR registrant classified as “Computer Communications Equipment” and organised in DE, formerly known as CISCO SYSTEMS, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 13F-HR dated 2026-10-15, and this view starts from filings dated on or before 2026-09-18. Nothing here is a recommendation to trade the security.

Vulnerability records for Cisco Unity Connection. Security flaws are catalogued by the U.S. National Vulnerability Database (NVD), run by NIST, not by the SEC. A keyword query of the NVD on Oct 25, 2026 returned 69 CVE entries whose descriptions mention Cisco Unity Connection; 16 of them were published in 2026, the newest being CVE-2026-76481 on 2026-10-21. Severity scores below are the CVSS base scores NVD lists; vendor advisories give fixed versions.

Business description, quoted from the 10-K filed 2026-09-02 by CISCO SYSTEMS, INC. (CIK 858877) (passage 2, continuing from the earlier excerpt) — source document:

Our products and technologies are grouped into the following categories: Networking, Security, Collaboration and Observability. In addition to our product offerings, we provide a broad range of services over the lifecycle of our products, including technical support services and professional services. Our customers include businesses of all sizes, public institutions, governments, and service providers, including hyperscalers. These customers often look to us as a strategic partner to help them use technology to differentiate themselves and drive positive business outcomes. Cisco was incorporated in California in 1984 and reincorporated in Delaware in 2021. Our headquarters are in San Jose, California. The mailing address of our headquarters is 170 West Tasman Drive, San Jose, California 95134-1706, and our telephone number at that location is (408) 526-4000.

Financial trend for CISCO SYSTEMS, INC. from quarterly and annual reports (three-month periods), periods 2025-10-25 to 2026-04-25: net income (loss) went from $2.86 billion (2025-10-25) to $3.37 billion (2026-04-25), a change of +17.9%; total assets went from $121.10 billion (2025-10-25) to $125.55 billion (2026-04-25), a change of +3.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 858877, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures CISCO SYSTEMS, INC. did not tag for that period.

Current reports. Of the 76 8-K or 6-K reports in CISCO SYSTEMS, INC.’s recent EDGAR index, the 4 listed here run from 2025-11-12 to 2026-04-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 858877 is on the EDGAR company page; the latest 10-K there is dated 2026-09-02 and the oldest filing in the recent index dates from 2020-06-19. One example from this record is the 8-K filed 2026-10-09 (document). Insider trades for CISCO SYSTEMS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Accendra health ach latest news october 2026

This section ties “Accendra health ach latest news october 2026” to ACCENDRA HEALTH INC/VA/ (ticker ACH), SEC Central Index Key 75252, an EDGAR registrant classified as “Wholesale-Medical, Dental & Hospital Equipment & Supplies” and organised in VA, formerly known as OWENS & MINOR INC/VA/. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a PRE 14A dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-20 by ACCENDRA HEALTH INC/VA/ (CIK 75252) — source document:

Accendra Health, Inc. (f/k/a Owens & Minor, Inc.) and subsidiaries (Accendra Health, we, us, our or the Company) is a leading nationwide provider of products, technology, and services that supports health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex, and acute health conditions. Together, our trusted brands, Apria and Byram Healthcare, bring nearly 90 years of combined experience in promoting health beyond the hospital in communities across the country. We are headquartered in Richmond, Virginia. The description of our business should be read in conjunction with the consolidated financial statements and supplementary data included in this Form 10-K.

Financial trend for ACCENDRA HEALTH INC/VA/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $9.96 billion (2022-12-31) to $2.76 billion (2025-12-31), a change of -72.3%; net income (loss) went from $22.39 million (2022-12-31) to -$1.10 billion (2025-12-31), a change of -5016.0%; total assets went from $5.39 billion (2022-12-31) to $2.45 billion (2025-12-31), a change of -54.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 75252, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures ACCENDRA HEALTH INC/VA/ did not tag for that period.

For the latest news, the fastest official source is the filing feed: ACCENDRA HEALTH INC/VA/ (CIK 75252) filed 154 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-09, and its overall latest filing is a PRE 14A dated 2026-10-19. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 154 8-K or 6-K reports in ACCENDRA HEALTH INC/VA/’s recent EDGAR index, the 4 listed here run from 2026-08-10 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 75252 is on the EDGAR company page; the latest 10-K there is dated 2026-02-20 and the oldest filing in the recent index dates from 2017-04-18. Insider trades for ACCENDRA HEALTH INC/VA/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aimei health technology co., ltd bullish and bearish analyst opinions

This section ties “Aimei health technology co., ltd bullish and bearish analyst opinions” to Aimei Health Technology Co., Ltd. (ticker AFJK, AFJKR, AFJKU), SEC Central Index Key 1979005, an EDGAR registrant classified as “Blank Checks” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a DEF 14A dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-05-04 by Aimei Health Technology Co., Ltd. (CIK 1979005) — source document:

We are a blank check company incorporated on April 27, 2023 as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. We seek to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Our efforts in identifying prospective target businesses will not be limited to a particular geographic region. On December 6, 2023, we consummated our initial public offering (“IPO”) of 6,000,000 units (the “IPO Units”). Each IPO Unit consists of one ordinary share, $0.0001 par value (the “Ordinary Share”), and one right (“Right”) to receive one-fifth (1/5) of one Ordinary Share upon the consummation of an initial business combination.

Financial trend for Aimei Health Technology Co., Ltd. from annual reports, periods 2023-12-31 to 2025-12-31: net income (loss) went from $2.55 million (2024-12-31) to $1.06 million (2025-12-31), a change of -58.5%; total assets went from $70.47 million (2023-12-31) to $12.10 million (2025-12-31), a change of -82.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1979005, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Aimei Health Technology Co., Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Aimei Health Technology Co., Ltd. (CIK 1979005) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-05-04. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 38 8-K or 6-K reports in Aimei Health Technology Co., Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-10-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1979005 is on the EDGAR company page; the latest 10-K there is dated 2026-05-04 and the oldest filing in the recent index dates from 2023-05-26. Insider trades for Aimei Health Technology Co., Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Albemarle tesla plug power intel strategic partnership october 2026

The October 2026 version of the Albemarle, Tesla, Plug Power and Intel “strategic partnership” search. Each company named is a separate SEC registrant reporting on its own; filing data as of Oct 25, 2026.

PLUG POWER INC (PLUG) filed the 8-K of 2026-06-15 covering 5.07 (submission of matters to a vote of security holders), 8.01 (other events); the 8-K of 2026-06-11 covering 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2023-12-31: FY revenue tagged at $891.34 million, profit or loss -$1.37 billion (10-K, 2026-03-02).

ALBEMARLE CORP (ALB) — EDGAR lists the 8-K of 2026-06-05 covering 5.02 (departure/election of directors or officers); the 8-K of 2026-05-08 covering 5.02 (departure/election of directors or officers), 5.07 (submission of matters to a vote of security holders), 9.01 (financial statements and exhibits). Year to 2023-12-31: annual sales of $9.62 billion, net result $1.57 billion (10-K, 2026-02-11).

Tesla, Inc. (TSLA) — EDGAR lists the 8-K of 2026-07-02 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-04-22 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2023-12-31: annual sales of $96.77 billion, net result $15.00 billion (10-K, 2026-01-29).

INTEL CORP (INTC) filed the 8-K of 2026-04-24 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits); the 8-K of 2026-04-23 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2023-12-30: FY revenue tagged at $54.23 billion, profit or loss $1.69 billion (10-K, 2026-01-23).

Item 2.01 count (completion of an acquisition or disposition of assets): PLUG 0, ALB 4 (latest 2026-03-06), TSLA 0, INTC 3 (latest 2025-09-15).

Updated Oct 25, 2026 ET

Cabaletta bio

This section ties “Cabaletta bio” to Cabaletta Bio, Inc. (ticker CABA), SEC Central Index Key 1759138, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-23 by Cabaletta Bio, Inc. (CIK 1759138) — source document:

We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA ® , or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentially reset the immune system. Based on clinical data reported to date, we believe our CABA ® platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.

Financial trend for Cabaletta Bio, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$52.98 million (2022-12-31) to -$167.86 million (2025-12-31), a change of -216.9%; total assets went from $116.97 million (2022-12-31) to $165.08 million (2025-12-31), a change of +41.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1759138, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Cabaletta Bio, Inc. did not tag for that period.

Cabaletta Bio, Inc. has 444 filings in its recent EDGAR index, including 7 annual reports and 21 quarterly reports; its newest filing is a 8-K from 2026-09-14.

Current reports. Of the 92 8-K or 6-K reports in Cabaletta Bio, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-03 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1759138 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2018-12-10. Insider trades for Cabaletta Bio, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Crane nxt cxt latest news october 2026

This section ties “Crane nxt cxt latest news october 2026” to Crane NXT, Co. (ticker CXT), SEC Central Index Key 25445, an EDGAR registrant classified as “Miscellaneous Fabricated Metal Products” and organised in DE, formerly known as Crane Holdings, Co. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-26 by Crane NXT, Co. (CIK 25445) — source document:

Crane NXT is a premier industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters most to its customers. The company is a pioneer in advanced, proprietary micro-optics technology for securing physical products, as well as digital authentication, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. We are comprised of two reporting segments: Crane Payment Innovations (“CPI”) and Security and Authentication Technologies (“SAT”). We are committed to delivering shareholder value by focusing on our proprietary and differentiated technology and investing in core businesses to capitalize on opportunities to enhance organic growth. We maintain a strong balance sheet with financial flexibility, allowing us the ability to expand the business through strategic acquisitions into higher-growth adjacencies.

Financial trend for Crane NXT, Co. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2022-12-31 at $3.37 billion; net income (loss) went from $204.90 million (2022-12-31) to $145.10 million (2025-12-31), a change of -29.2%; total assets went from $2.13 billion (2022-12-31) to $3.12 billion (2025-12-31), a change of +46.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 25445, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Crane NXT, Co. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Crane NXT, Co. (CIK 25445) filed 108 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-07, and its overall latest filing is a 8-K dated 2026-10-07. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 108 8-K or 6-K reports in Crane NXT, Co.’s recent EDGAR index, the 4 listed here run from 2026-05-28 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 25445 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2015-01-29. Insider trades for Crane NXT, Co. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cvr partners uan latest news october 2026

This section ties “Cvr partners uan latest news october 2026” to CVR PARTNERS, LP (ticker UAN), SEC Central Index Key 1425292, an EDGAR registrant classified as “Agricultural Chemicals” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-07-29. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-18 by CVR PARTNERS, LP (CIK 1425292) — source document:

CVR Partners, LP (“CVR Partners” or the “Partnership”) is a Delaware limited partnership formed in 2011 by CVR Energy, Inc. (together with its subsidiaries, but excluding the Partnership and its subsidiaries, “CVR Energy”) to own, operate and grow its nitrogen fertilizer business. The Partnership produces and distributes nitrogen fertilizer products, which are used by farmers to improve the yield and quality of their crops, primarily corn and wheat. The Partnership produces these products at two manufacturing facilities, one located in Coffeyville, Kansas operated by its wholly owned subsidiary, Coffeyville Resources Nitrogen Fertilizers, LLC (“CRNF”) (the “Coffeyville Facility”) and one located in East Dubuque, Illinois operated by its wholly owned subsidiary, East Dubuque Nitrogen Fertilizers, LLC (“EDNF”) (the “East Dubuque Facility”, and together with the Coffeyville Facility, the “Facilities”).

Financial trend for CVR PARTNERS, LP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $835.58 million (2022-12-31) to $606.04 million (2025-12-31), a change of -27.5%; net income (loss) went from $286.80 million (2022-12-31) to $98.66 million (2025-12-31), a change of -65.6%; total assets went from $1.10 billion (2022-12-31) to $969.46 million (2025-12-31), a change of -11.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1425292, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures CVR PARTNERS, LP did not tag for that period.

For the latest news, the fastest official source is the filing feed: CVR PARTNERS, LP (CIK 1425292) filed 187 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-07-29, and its overall latest filing is a 10-Q dated 2026-07-29. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 187 8-K or 6-K reports in CVR PARTNERS, LP’s recent EDGAR index, the 4 listed here run from 2026-03-18 to 2026-07-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1425292 is on the EDGAR company page; the latest 10-K there is dated 2026-02-18 and the oldest filing in the recent index dates from 2008-02-28. Insider trades for CVR PARTNERS, LP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Descartes-08 cartesian therapeutics latest news october 2026

This section ties “Descartes-08 cartesian therapeutics latest news october 2026” to Cartesian Therapeutics, Inc. (ticker RNAC), SEC Central Index Key 1453687, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as SELECTA BIOSCIENCES INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-29, and this view starts from filings dated on or before 2026-05-06. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-09 by Cartesian Therapeutics, Inc. (CIK 1453687) (passage 2, continuing from the earlier excerpt) — source document:

In connection with the Merger and pursuant to the Merger Agreement, the Company (which was known as Selecta Biosciences, Inc. until immediately prior to the Merger) changed its corporate name to Cartesian Therapeutics, Inc. Overview We are a late clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases. We leverage our proprietary technology and manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell’s genetic material. Our cell therapies are designed to be dosed repeatedly like conventional drugs, administered in an outpatient setting and given without pre-treatment chemotherapy required with many conventional cell therapies.

Financial trend for Cartesian Therapeutics, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $452,000 (2025-09-30) to $0 (2026-06-30), a change of -100.0%; net income (loss) went from -$35.90 million (2025-09-30) to $15.77 million (2026-06-30), a change of +143.9%; total assets went from $372.68 million (2025-09-30) to $318.63 million (2026-06-30), a change of -14.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1453687, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Cartesian Therapeutics, Inc. did not tag for that period.

Current reports. Of the 172 8-K or 6-K reports in Cartesian Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-09 to 2026-05-26, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1453687 is on the EDGAR company page; the latest 10-K there is dated 2026-03-09 and the oldest filing in the recent index dates from 2009-01-05. One example from this record is the SCHEDULE 13G/A filed 2026-07-22 (document). Insider trades for Cartesian Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

F5 big-ip ltm cve 2026

This section ties “F5 big-ip ltm cve 2026” to F5, INC. (ticker FFIV), SEC Central Index Key 1048695, an EDGAR registrant classified as “Computer Communications Equipment” and organised in WA, formerly known as F5 NETWORKS, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-15. Nothing here is a recommendation to trade the security.

Vulnerability records for F5 BIG-IP LTM. Security flaws are catalogued by the U.S. National Vulnerability Database (NVD), run by NIST, not by the SEC. A keyword query of the NVD on Oct 25, 2026 returned 209 CVE entries whose descriptions mention F5 BIG-IP LTM; 1 of them were published in 2026, the newest being CVE-2026-22549 on 2026-02-04. Severity scores below are the CVSS base scores NVD lists; vendor advisories give fixed versions.

Business description, quoted from the 10-K filed 2025-11-25 by F5, INC. (CIK 1048695) — source document:

F5 is a multicloud application delivery and security provider committed to bringing a better digital world to life. F5 partners with the world’s largest, most advanced organizations to optimize and secure every application and Application Programming Interface ("API") anywhere, including on-premises, in the cloud, and at the network edge. F5 enables businesses to continuously stay ahead of threats while delivering exceptional, secure digital experiences for their customers. Our application delivery and security solutions are available in a range of deployment and consumption models. We sell packaged software in perpetual, subscription, and usage-based consumption models. We also sell our solutions in software-as-a-service ("SaaS") and managed services deployment models with subscription and usage-based consumption models.

Financial trend for F5, INC. from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from $2.70 billion (2022-09-30) to $3.09 billion (2025-09-30), a change of +14.5%; net income (loss) went from $322.16 million (2022-09-30) to $692.38 million (2025-09-30), a change of +114.9%; total assets went from $5.28 billion (2022-09-30) to $6.32 billion (2025-09-30), a change of +19.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1048695, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures F5, INC. did not tag for that period.

Current reports. Of the 61 8-K or 6-K reports in F5, INC.’s recent EDGAR index, the 4 listed here run from 2026-04-28 to 2026-07-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1048695 is on the EDGAR company page; the latest 10-K there is dated 2025-11-25 and the oldest filing in the recent index dates from 2020-02-04. Insider trades for F5, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Harrow inc hrow press release news

This section ties “Harrow inc hrow press release news” to HARROW, INC. (ticker HROW), SEC Central Index Key 1360214, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as HARROW HEALTH, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-05, and this view starts from filings dated on or before 2026-06-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-02 by HARROW, INC. (CIK 1360214) (passage 2, continuing from the earlier excerpt) — source document:

By combining our culture of creativity, entrepreneurship and groundbreaking innovation with operational discipline and strong financial performance, we are building a future where life-changing ophthalmic treatments are within reach for all. Branded Ophthalmic Pharmaceuticals Over the past several years, we have expanded our portfolio of the U.S. Food and Drug Administration (the “FDA”)-approved ophthalmic products through acquisitions, licensing transactions, and internal investment. These efforts are focused primarily on the U.S. and Canadian markets. We believe continued investment in our branded portfolio supports our ability to offer eyecare prescribers and patients access to a broader range of ophthalmic therapies across multiple disease states. We own U.S. commercial rights to the following products, which we market and sell: ● IHEEZO ® (chloroprocaine hydrochloride ophthalmic gel) 3%, a low-viscosity gel indicated for ocular surface anesthesia. ● VEVYE ® (cyclosporine ophthalmic solution) 0.1%, utilizes a novel water-free vehicle (perfluorobutylpentane) based on semifluorinated alkanes, indicated for the treatment of the signs and symptoms associated with dry eye disease. ● TRIESENCE ® (triamcinolone acetonide injectable suspension) 40 mg/ml, a steroid injection for the treatment of certain ophthalmic diseases and for visualization during vitrectomy.

Financial trend for HARROW, INC. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $1.02 million (2025-09-30) to -$17.27 million (2026-06-30), a change of -1793.1%; total assets went from $363.07 million (2025-09-30) to $416.82 million (2026-06-30), a change of +14.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1360214, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures HARROW, INC. did not tag for that period.

Current reports. Of the 268 8-K or 6-K reports in HARROW, INC.’s recent EDGAR index, the 4 listed here run from 2026-03-27 to 2026-06-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1360214 is on the EDGAR company page; the latest 10-K there is dated 2026-03-02 and the oldest filing in the recent index dates from 2006-07-21. One example from this record is the 10-Q filed 2026-08-10 (document). Insider trades for HARROW, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hemab therapeutics ceo latest news

This section ties “Hemab therapeutics ceo latest news” to Hemab Therapeutics Holdings, Inc. (ticker COAG), SEC Central Index Key 2114044, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-25, and this view starts from filings dated on or before 2026-08-05. Nothing here is a recommendation to trade the security.

For the latest news, the fastest official source is the filing feed: Hemab Therapeutics Holdings, Inc. (CIK 2114044) filed 5 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-24, and its overall latest filing is a 4 dated 2026-09-25. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 5 8-K or 6-K reports in Hemab Therapeutics Holdings, Inc.’s recent EDGAR index, the 1 listed here run from 2026-05-04 to 2026-05-04, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 50 recent EDGAR filings, Hemab Therapeutics Holdings, Inc. most often filed 3 (12), 4 (10), SCHEDULE 13G (8), 8-K (5). A selection from 2026-06-17 to 2026-08-11:

The full record for CIK 2114044 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-27. One example from this record is the SCHEDULE 13G filed 2026-08-14 (document). Insider trades for Hemab Therapeutics Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Paranovus entertainment technology ltd. bullish and bearish analyst opinions

This section ties “Paranovus entertainment technology ltd. bullish and bearish analyst opinions” to Paranovus Entertainment Technology Ltd. (ticker PAVS), SEC Central Index Key 1751876, an EDGAR registrant classified as “Services-Computer Processing & Data Preparation” and organised in Cayman Islands, formerly known as Happiness Development Group Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 20-F dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-08-14 by Paranovus Entertainment Technology Ltd. (CIK 1751876) — source document:

We were formed under the name of “Happiness Biotech Group Limited” on February 9, 2018, under the laws of the Cayman Islands. In October 2022, we changed the name from “Happiness Biotech Group Limited” to “Happiness Development Group Limited”. In March 2023, our registered name was changed to “Paranovus Entertainment Technology Ltd.” Our registered office is at Harnes Fiduciary (Cayman) Limited, with its offices located at 4 th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman, KY1-1002M Cayman Islands. Our principal executive offices are located at 1177 6th avenue, floor 5, New York, NY 10036. Our telephone number at that address is + 1-516-951-9074. Our company website is https://pavs.ai.

Financial trend for Paranovus Entertainment Technology Ltd. from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from $0 (2023-03-31) to $14.60 million (2026-03-31); net income (loss) went from -$71.74 million (2023-03-31) to -$12.73 million (2026-03-31), a change of +82.2%; total assets went from $36.34 million (2023-03-31) to $36.87 million (2026-03-31), a change of +1.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1751876, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Paranovus Entertainment Technology Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Paranovus Entertainment Technology Ltd. (CIK 1751876) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-08-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 78 8-K or 6-K reports in Paranovus Entertainment Technology Ltd.’s recent EDGAR index, the 4 listed here run from 2026-06-15 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1751876 is on the EDGAR company page; the latest 20-F there is dated 2026-08-14 and the oldest filing in the recent index dates from 2018-09-04. Insider trades for Paranovus Entertainment Technology Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Perusahaan perseroan (persero) pt telekomunikasi indonesia tbk bullish and bearish analyst opinions

This section ties “Perusahaan perseroan (persero) pt telekomunikasi indonesia tbk bullish and bearish analyst opinions” to PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK (ticker TLK), SEC Central Index Key 1001807, an EDGAR registrant classified as “Telephone Communications (No Radiotelephone)” and organised in an unstated jurisdiction, formerly known as TELECOMMUNICATIONS INDONESIA. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-05-15 by PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK (CIK 1001807) — source document:

Profile of Telkom ​ Telkom is the largest telecommunications company in Indonesia, in terms of revenue and number of subscribers, as of December 31, 2025. We provide fixed and mobile telecommunications services and solutions and ancillary services. We are innovative and continue to strengthen and optimize our portfolio businesses, services and solutions by creating strategic programs that aim to maximize synergies and active portfolio management. Our existential purpose is to build Indonesia into a more prosperous and competitive nation while delivering the best value to our stakeholders. Our long-term vision is to be the most preferred digital telecommunications company and empower Indonesian society. To achieve this vision, we focus on three missions that cover many aspects of empowering society, including rapidly building sustainable digital infrastructure and smart platforms that are affordable and accessible to a wide range of customers, nurturing best-in-class digital talents to help develop Indonesia’s digital capabilities and increase the adoption of digital technologies and services, and orchestrating a comprehensive digital ecosystem to deliver a superior customer experience .

Financial trend for PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK from annual reports, periods 2021-12-31 to 2024-12-31: net income (loss) went from 34,099,000,000,000 IDR (2021-12-31) to 30,725,000,000,000 IDR (2024-12-31), a change of -9.9%; total assets went from 276,158,000,000,000 IDR (2021-12-31) to 299,297,000,000,000 IDR (2024-12-31), a change of +8.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1001807, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK (CIK 1001807) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-05-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 573 8-K or 6-K reports in PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK’s recent EDGAR index, the 4 listed here run from 2026-10-02 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1001807 is on the EDGAR company page; the latest 20-F there is dated 2026-05-15 and the oldest filing in the recent index dates from 2002-01-29. Insider trades for PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Quartzsea acquisition corporation bullish and bearish analyst opinions

This section ties “Quartzsea acquisition corporation bullish and bearish analyst opinions” to Quartzsea Acquisition Corp (ticker QSEA, QSEAR, QSEAU), SEC Central Index Key 2047455, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-16 by Quartzsea Acquisition Corp (CIK 2047455) — source document:

We are a Cayman Islands exempted company with limited liability incorporated on November 5, 2024. We are formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses (the “Business Combination”). Initial Public Offering and Private Placement In November 2024, the Company issued 1,725,000 shares of ordinary shares, $0.0001 per share to the Sponsor, the founder shares, for an aggregated consideration of $25,000, or approximately $0.0145 per share. On February 12, 2025, the Company and the Sponsor entered into the First Amendment to the Subscription Agreement, pursuant to which the purchased amount of founder shares was adjusted to 2,415,000 ordinary shares.

Financial trend for Quartzsea Acquisition Corp from annual reports, periods 2024-11-30 to 2025-11-30: net income (loss) was tagged only for 2025-11-30 at $510,959; total assets went from $516,000 (2024-11-30) to $85.34 million (2025-11-30), a change of +16438.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2047455, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Quartzsea Acquisition Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Quartzsea Acquisition Corp (CIK 2047455) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Quartzsea Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 7 such filings (424B4, 425, S-1, S-1/A, S-1MEF) appear in its recent index, the newest dated 2026-05-15.

Current reports. Of the 14 8-K or 6-K reports in Quartzsea Acquisition Corp’s recent EDGAR index, the 4 listed here run from 2026-08-25 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2047455 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-09 and the oldest filing in the recent index dates from 2024-12-23. Insider trades for Quartzsea Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Solarmax technology inc. common stock bullish and bearish analyst opinions

This section ties “Solarmax technology inc. common stock bullish and bearish analyst opinions” to SolarMax Technology, Inc. (ticker SMXT), SEC Central Index Key 1519472, an EDGAR registrant classified as “Construction - Special Trade Contractors” and organised in NV. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-09. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-06 by SolarMax Technology, Inc. (CIK 1519472) — source document:

We are an integrated solar and renewable energy company. A solar energy system retains the direct current (DC) electricity from the sun and converts it to alternating current (AC) electricity that can be used to power residential homes and commercial businesses. The solar business is based on the ability of the users of solar energy systems to save on energy costs and reduce their carbon imprint as compared with power purchased from the local electricity utility company. We were founded in 2008 to engage in the solar business in the United States, where our business is primarily conducted. The photovoltaic market in the United States has experienced significant growth with the help of the Inflation Reduction Act, with solar accounting for approximately 16% of the country’s electricity generation.

Financial trend for SolarMax Technology, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $44.72 million (2022-12-31) to $90.98 million (2025-12-31), a change of +103.5%; net income (loss) went from -$6.87 million (2022-12-31) to -$6.33 million (2025-12-31), a change of +8.0%; total assets went from $61.48 million (2022-12-31) to $91.29 million (2025-12-31), a change of +48.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1519472, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SolarMax Technology, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SolarMax Technology, Inc. (CIK 1519472) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-09, and the most recent 10-K annual report was filed 2026-04-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 33 8-K or 6-K reports in SolarMax Technology, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-05 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1519472 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-14 and the oldest filing in the recent index dates from 2011-05-05. Insider trades for SolarMax Technology, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Spectral ai mdai latest news october 2026

This section ties “Spectral ai mdai latest news october 2026” to Spectral AI, Inc. (ticker MDAI, MDAIW), SEC Central Index Key 1833498, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE, formerly known as Rosecliff Acquisition Corp I. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-29. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-25 by Spectral AI, Inc. (CIK 1833498) — source document:

We are an AI company focused on predictive medical diagnostics. Our DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound’s capacity to heal or not-heal by a specified time point in the future. Our DeepView System’s output is specifically engineered to assist the health care professional in making a more accurate, timely and informed decision regarding the treatment of the patient’s wounds. Our focus is on our burn indication. We were notified that our DeepView System, comprised of the multispectral imaging (“MSI”) component integrated with the predictive AI-Burn ® software component, received United Kingdom Conformity Assessed (UKCA) marking for use in the United Kingdom for burn indications on February 22, 2024.

Financial trend for Spectral AI, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $25.37 million (2022-12-31) to $19.65 million (2025-12-31), a change of -22.5%; net income (loss) went from -$2.91 million (2022-12-31) to -$7.57 million (2025-12-31), a change of -160.0%; total assets went from $18.72 million (2022-12-31) to $21.41 million (2025-12-31), a change of +14.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1833498, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Spectral AI, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Spectral AI, Inc. (CIK 1833498) filed 65 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-15, and its overall latest filing is a 4 dated 2026-09-29. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 65 8-K or 6-K reports in Spectral AI, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-01 to 2026-09-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1833498 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2020-12-23. Insider trades for Spectral AI, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Surgery partners sgry latest news october 2026

This section ties “Surgery partners sgry latest news october 2026” to Surgery Partners, Inc. (ticker SGRY), SEC Central Index Key 1638833, an EDGAR registrant classified as “Services-General Medical & Surgical Hospitals, NEC” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-02 by Surgery Partners, Inc. (CIK 1638833) — source document:

Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company." We are a leading healthcare services company with an integrated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. We are one of the largest and fastest growing surgical services businesses in the United States ("U.S."), with more than 200 locations in 30 states, including ambulatory surgery centers ("ASCs"), short-stay surgical hospitals ("surgical hospitals"), and multi-specialty physician practices, among others.

Financial trend for Surgery Partners, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$54.60 million (2022-12-31) to -$77.90 million (2025-12-31), a change of -42.7%; total assets went from $6.68 billion (2022-12-31) to $8.12 billion (2025-12-31), a change of +21.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1638833, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Surgery Partners, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Surgery Partners, Inc. (CIK 1638833) filed 140 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-17, and its overall latest filing is a SCHEDULE 13G dated 2026-10-13. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 140 8-K or 6-K reports in Surgery Partners, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-05 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1638833 is on the EDGAR company page; the latest 10-K there is dated 2026-03-02 and the oldest filing in the recent index dates from 2015-04-22. Insider trades for Surgery Partners, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Arcadia biosciences, inc. bullish and bearish analyst opinions

This section ties “Arcadia biosciences, inc. bullish and bearish analyst opinions” to Arcadia Biosciences, Inc. (ticker RKDA), SEC Central Index Key 1469443, an EDGAR registrant classified as “Crude Petroleum & Natural Gas” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a S-8 dated 2026-09-30. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-26 by Arcadia Biosciences, Inc. (CIK 1469443) — source document:

Arcadia has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Since acquiring the assets of Zola in May 2021, Arcadia has provided consumers with a way to rehydrate, reset, and reenergize with Zola coconut water products. Previously, Arcadia developed products, primarily in wheat, which it commercialized through the sale of food products, trait licensing and royalty agreements. On May 14, 2024, Arcadia sold its non-GMO Resistant Starch (“RS”) durum wheat trait to longtime partner Corteva Agriscience (“Corteva”) for total cash consideration of $4.0 million. Refer to Note 11 to the consolidated financial statements for further details of the transaction.

Financial trend for Arcadia Biosciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $7.42 million (2022-12-31) to $4.86 million (2025-12-31), a change of -34.5%; net income (loss) went from -$15.38 million (2022-12-31) to -$2.34 million (2025-12-31), a change of +84.8%; total assets went from $28.92 million (2022-12-31) to $6.55 million (2025-12-31), a change of -77.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1469443, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Arcadia Biosciences, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Arcadia Biosciences, Inc. (CIK 1469443) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 138 8-K or 6-K reports in Arcadia Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-10 to 2026-09-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1469443 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2009-08-04. Insider trades for Arcadia Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gsr v acquisition corp. bullish and bearish analyst opinions

This section ties “Gsr v acquisition corp. bullish and bearish analyst opinions” to GSR V Acquisition Corp. (ticker GSRV, GSRVR, GSRVU), SEC Central Index Key 2111762, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-07. Nothing here is a recommendation to trade the security.

Financial trend for GSR V Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$56,685 (2026-03-31) to $786,553 (2026-06-30), a change of +1487.6%; total assets went from $75,916 (2026-03-31) to $232.80 million (2026-06-30), a change of +306560.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2111762, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures GSR V Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on GSR V Acquisition Corp. (CIK 2111762) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for GSR V Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-05-14.

Current reports. Of the 3 8-K or 6-K reports in GSR V Acquisition Corp.’s recent EDGAR index, the 3 listed here run from 2026-05-18 to 2026-07-07, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 29 recent EDGAR filings, GSR V Acquisition Corp. most often filed SCHEDULE 13G (7), 3 (5), 8-K (3), 10-Q (2). A selection from 2026-08-14 to 2026-10-07:

The full record for CIK 2111762 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-03-30. Insider trades for GSR V Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET